Is there a path forward for mGlu(2) positive allosteric modulators for the treatment of schizophrenia?
Ontology highlight
ABSTRACT: Two recent Phase II results show opposing outcomes for the potential of activators of mGlu2 in the treatment of schizophrenia. The first outcome revealed that Eli Lilly's mGlu2/3 agonist, pomaglumetad methionil (LY2140023), failed to meet the primary efficacy end point. The second report showed the mGlu2 positive allosteric modulator (PAM) from Addex (ADX71149) in conjunction with Janssen Research & Development met the primary objectives of safety, tolerability and demonstrated an effect on negative symptoms in patients.
SUBMITTER: Hopkins CR
PROVIDER: S-EPMC3582287 | biostudies-other | 2013 Feb
REPOSITORIES: biostudies-other
ACCESS DATA